糖皮质激素对重症肌无力患者血清IL-6及免疫球蛋白的影响

目的：探讨糖皮质激素（GC）对重症肌无力（MG）患者外周血白细胞介素-6（IL-6）和免疫球蛋白的影响。方法：治疗组为34例MG患者，采用GC治疗，疗程2个月，观察治疗前后临床症状改善情况及外周血IL-6和免疫球蛋白的水平。结果：经治疗2个月后，治疗组临床总有效率为82%（28/34）。治疗前MG患者血清IL-6、IgG1、IgG3均高于健康组，差异均有统计学意义（P〈0.05）， IgM、IgA、IgG2、IgG4与健康组比较差异均无统计学意义（P〉0.05）；经2个月治疗，血清IL-6、IgG1浓度降低，较治疗前差异有统计学意义（P〈0.01）；IL-6与IgG1在治疗前及治疗后有正相关性，与IgG3无相关性。结论：GC可通过抑制MG患者体内IL-6和免疫球蛋白的产生，部分调节患者的免疫功能。

Impact of glucocorticoid on IL-6 and immunoglobulin in patients with myasthenia gravis

To investigate the impact of glucocorticoid on IL-6 and immunoglobulin in patients with myasthenia gravis （MG）. Methods： Thirty-four cases of MG in the treated group received glucocorticoid therapy for 2 months. Alterations in symptoms and peripheral blood levels of IL-6 and immunoglobulin were observed before and after treatment. The relationship between IL-6 and the others （IgG1,IgG3）of the patient were analyzed. Results： After two months of treatment,total effective rate in the treated group was 82%（28/34）;serum levels of IL-6,IgG1 and IgG3 were higher in the MG groups than that in the healthy group（P〈0 . 05）. No statistical significance was noted in serum levels of IgM, IgA, IgG2 and IgG4 between the MG groups and the healthy group （P〉0.05）. After 2 months of treatment, significant differences was noted before and after treatment in IL-6 and IgG1 levels of the treated group（P〈0.01）. There was correlation between IL-6 and IgG1, but was not related to IgG3 before and after treatment in myasthenia gravis.Conclusion：Glucocorticoid can effectively regulate the function of both cellular and humoral immunity by decreasing the production of IL- 6 and immunoglobulin .